A phase III trial of taxol, etoposide phosphate and carboplatin (TEC) versus carboplatin, etoposide phosphate and vincristine (CEV) in previously untreated small cell lung cancer (SCLC)

Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma

“…Results from a large, randomized trial in Germany comparing this regimen with combined carboplatin, etoposide, and vincristine will be available in the near future. 24 In addition, similar randomized trials have been initiated in cooperative groups in the United States. The sequential use of noncross-resistant, two-drug combinations is an alternate strategy that may avoid the toxicity of three-drug regimens and allow the administration of optimum doses of all drugs.…”

Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer

“…In a randomized, phase III study in 373 evaluable patients so far, the ORR of patients treated with paclitaxel, carboplatin, and etoposide was 93% compared to 87% for patients treated with vincristine, carboplatin, and etoposide. The hematologic toxicities, thrombocytopenia and anemia, occurred less frequently in the paclitaxel arm [22].…”